Simplifying Global Compliance
Fed Circuit: ‘Safe Harbor’ Provision Is Broad: Amphastar, Momenta Dispute
A 2–1 final federal appeals court decision that lifts an injunction barring Watson Pharmaceuticals and Amphastar from selling a generic version of Sanofi’s blockbuster blood-thinner Lovenox hinged on an expansive interpretation of Hatch-Waxman’s “safe harbor” provision — a move that could have wide-ranging implications for all patent holders, warns Momenta Pharmaceuticals, which lost its appeal.
To View This Article:
Subscribe To Generic Line
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing